Navigation Links
MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
Date:1/31/2008

applicable securities laws in Canada, (collectively referred to as "forward-looking statements"). Statements, other than statements of historical fact, are forward-looking statements and include, without limitation, statements regarding our strategy, future operations, timing and completion of clinical trials, prospects, plans and objectives of management. The words "anticipates", "believes", "budgets", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "projects", "schedule", "should", "will", "would" and similar expressions are often intended to identify forward-looking statements, which include underlying assumptions, although not all forward-looking statements contain these identifying words. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other things contemplated by the forward-looking statements will not occur.

Although our management believes that the expectations represented by such forward-looking statements are reasonable, there is significant risk that the forward-looking statements may not be achieved, and the underlying assumptions thereto will not prove to be accurate. Forward-looking statements in this news release include, but are not limited to, statements concerning our expectations for: increasing the celgosivir dose to 600mg being an important development step for the optimization and advancement of celgosivir; our plans to add approximately six patients at 600mg dose in the celgosivir Phase II viral kinetics study and having results from the study in the third quarter 2008; Cadence Pharmaceuticals completing enrollment in the CLIRS trial in the second quarter of 2008, with results available in the second half of 2008; and Cutanea Life Sciences' plans to advance omiganan for the treatment of rosacea to Phase III clinical developme
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
2. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
3. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
7. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
8. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
9. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
10. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
11. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... The Alliance for Safe Biologic ... European physicians at the "1 ST EuropaBio ... at the Spanish Ministry of Health, Social Services ... the Spanish Bioindustry Association (ASEBIO), included regulators from ... oncology and rheumatology societies, representatives from a hospital ...
(Date:11/26/2014)... Charlotte, NC (PRWEB) November 25, 2014 ... High Intensity Focused Ultrasound (HIFU) devices, recently participated ... “ Small Renal Mass 360° .” Key opinion ... and therapeutic advances related to small renal masses ... learn about different ablative technologies in hands-on labs. ...
(Date:11/26/2014)... Miles Holder, formerly of Micron Research and ... team as Sales/Marketing Manager. Mr. Holder has over 25 ... the graphite industry. , “We are thrilled to be ... Trinkley, VP of Market and Product Development for Graphel ... the graphite industry, along with his proven track record ...
(Date:11/26/2014)... , Nov. 25, 2014 Bio-Techne Corporation ... has appointed Robert Gavin to serve in ... the Protein Platforms Division.  Mr. Gavin will be responsible ... segment, which includes the ProteinSimple business acquired in July ... San Jose, California -based ProteinSimple develops ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... 2011 The New York Stem Cell Summit is releasing ... the press and the general public understand more accurately the ... the United States today. Approximately 1 million patients ... mid-1980s in the United States. Harvesting stem ...
... 2011 Renmatix , the leading producer of cellulosic sugars, ... fuels company Amyris , has joined the Renmatix Board of ... Year" by the Philadelphia Business Journal , will fill the ... Melo comes to the Renmatix Board of Directors with rare ...
... Sept. 13Researchers at Vanderbilt University have developed a new technique ... biological tissue at multiple points simultaneously, a method that could ... grow and change shape. UV lasers are a ... make incisions by vaporizing one point at a time in ...
Cached Biology Technology:New York Stem Cell Summit Issues Adult Stem Cell Fact Sheet 2Amyris Chief Joins Renmatix BoD, New CFO Added to Company 2
(Date:11/4/2014)... nature, the right amount of death at the right ... according to new research that could help in understanding ... stocks. , In a paper in the journal ... researcher and European colleagues conclude that the kind of ... loss of individuals, or mortality, depends on the size ...
(Date:11/4/2014)... A majority of Madagascar,s 101 species of lemurs are ... for the rainforests they call home. A new study ... can have on rainforest tree populations, which raises concerns ... the region,s rich biodiversity. , A large proportion of ... Lemurs in turn disperse the seeds of their ...
(Date:11/3/2014)... weight and preterm birth are linked to increased risk ... in the American College of Rheumatology (ACR) journal, ... weight and pre-term babies were not at greater risk ... , According to the ACR, 27 million Americans over ... Symptoms of OA range from mild to severe and ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Preterm, low birth-weight babies may need new hips in adulthood 2
... incredibly temperature sensitive and can perceive changes of as little ... 8th issue of the journal Cell , a Cell ... rise, but also coordinate an appropriate response -- activating hundreds ... about the way that their DNA is packaged. The ...
... gardening world it may have always been considered a fact, ... watering your garden in the midday sun can lead to ... in New Phytologist , provides an answer that not ... for forest fires and human sunburn. "The problem ...
... project E! 3184 Odysseus has developed systems to ... tumours or other pathologies, from MRI or CT-scans. The ... location, for consultation in real time just before surgery. ... with the best possible diagnostic support, before real surgery ...
Cached Biology News:How plants 'feel' the temperature rise 2Can a drop of water cause sunburn or fire? 2A virtual liver, a better chance of life 2A virtual liver, a better chance of life 3